Malaysia To Receive 3.5 Million CanSino Covid-19 Vaccine Doses Starting April

Sources: Ministry of Health Malaysia (MoH) Facebook

Malaysia will obtain 3.5 million of CanSino Coid-19 vaccine from China in stages starting in April with the first delivery of 150,000 doses.

Minister of Health, Dr. Adham Baba said that the CanSino Covid-19 vaccine is the only vaccine that requires one dose, which will benefit 3.5 million Malaysians with the second delivery coming in with 350,000 doses in May.

The first and second delivery will be a finished vaccine meanwhile the next delivery will be in bulk. A local company, Solutions Biologics Sdn. Bhd. will fill and finish the vaccines in the country like Pharmaniaga did with Sinovac.

“Solutions Biologics will gain the benefit of the vaccine transfer bottling technology, which is the Convidecia, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), that was developed by CanSino Biologic Inc. in Tianjin, China.

However, this company must meet all the terms and regulations set by the National Pharmaceutical Regulatory Division (NPRA) and the Drug Control Authority (DCA) before enabling the supply of this vaccine. This is due to the emphasis on efficacy, safety and quality,” he said.

The main use for the CanSino Covid-19 vaccine will be prioritised for those who are in the rural areas and for those who do not have the ability to come twice to get the vaccine the second time. Based on the NPRA clinical research, the vaccine can accommodate the vaccination roll-out in the country.

“We hope CanSino Biologic will provide all data to the NPRA and the DCA to enable these authorities to submit their reports as we cannot delay the purchase of this single dose vaccine due to the urgent need for phase two and three under the National Covid-19 Vaccination Programme,” he concluded.

Previous articleUiTM Energy and Facilities Signs 21-year Solar Power Purchase Agreement With Ingress Corporation’s Subsidiaries
Next articleDNeX and CGP Fund To Acquire SilTerra For RM273 Million

LEAVE A REPLY

Please enter your comment!
Please enter your name here